Abstract：【Objective】 To investigate the effect of different active vitamin D3 combined with prednisone acetate and cyclophosphamide on membranous nephropathy (MN),oxidative stress and markers of renal podocyte injury.【Methods】 A total of 124 MN patients were randomly divided into observation group and control group,62 patients in each group.The two groups were treated with conventional methods,cyclophosphamide and prednisone acetate.The control group was treated with alfacalciferol,and the observation group was treated with calcitriol.The therapeutic effects,markers of oxidative stress and renal podocyte injury before and after treatment,and drug safety during treatment were compared between the two groups. 【Results】 The urinary protein of the two groups after treatment was lower than that before treatment (P<0.05),and that of the observation group was lower than that of the control group (P<0.05).The total effective rate of the observation group was higher than that of the control group (P<0.05).The levels of advanced protein oxidation products (AOPP) and reactive oxygen species (ROS) in the two groups after treatment were lower than those before treatment (P<0.05),and those in the observation group were lower than those in the control group (P<0.05); After treatment,the level of superoxide dismutase (SOD) in both groups was higher than that before treatment (P<0.05),and that in the observation group was higher than that in the control group (P<0.05).The levels of urine podophyxin and Nephrin in the two groups after treatment were lower than those before treatment (P<0.05),and those in the observation group were lower than those in the control group (P<0.05).There was no significant difference in the incidence of total adverse reactions between the two groups (P>0.05).【Conclusion】 The combination of calcitriol, prednisone acetate and cyclophosphamide in the treatment of MN can enhance the curative effect,improve the oxidative stress and renal podocyte injury in patients with MN,and has good safety.
周淑娟, 黄静瑾. 不同活性维生素D3联合醋酸波尼松、环磷酰胺治疗膜性肾病的疗效比较[J]. 医学临床研究, 2023, 40(1): 105-107.
ZHOU Shu-juan, HUANG Jing-jin. Comparison of Therapeutic Effects of Different Active Vitamin D3 Combined with Prednisone Acetate and Cyclophosphamide on Membranous Nephropathy. JOURNAL OF CLINICAL RESEARCH, 2023, 40(1): 105-107.
[1] SALANT D J.Unmet challenges in membranous nephropathy[J].Curr Opin Nephrol Hypertens,2019,28(1):70-76. [2] SEITZ-POLSKII B,DAHAN K,DEBIEC H,et al.High-dose rituximab and early remission in PLA2R1-related membranous nephropathy[J].Clin J Am Soc Nephrol,2019,14(8):1173-1182. [3] XIE J,LIU L,MLADKOVA N,et al.The genetic architecture of membranous nephropathy and its potential to improve non-invasive diagnosis[J].Nat Commun,2020,11(1):1600-1611. [4] 赵晔,于磊,王秀颖,等.维生素D3治疗糖尿病肾病患者的疗效及肾组织足细胞损伤与ROS,AOPP,SOD的相关性分析[J].疑难病杂志,2020,19(1):36-40. [5] 李晓勇.两种血药浓度他克莫司在特发性Ⅱ期膜性肾病临床疗效观察[J].临床肾脏病杂志,2019,19(8):594-597. [6] 刘晓城.肾脏病诊疗指南[M].北京:科学出版社,2005:39-65. [7] TRUJILLO H,ALONSO M,PRAGA M.New ways of understanding membranous nephropathy[J].Nephron,2020,144(6):261-271. [8] CAZA T N,HASSEN S I,DVANAJSCAK Z,et al.NELL1 is a target antigen in malignancy-associated membranous nephropathy[J].Kidney Int,2021,99(4):967-976. [9] JIN L W,PAN M,YE H Y,et al.Down-regulation of the long non-coding RNA XIST ameliorates podocyte apoptosis in membranous nephropathy via the miR-217-TLR4 pathway[J].Exp Physiol,2019,104(2):220-230. [10] ZHOU L,CHEN X,LU M,et al.Wnt/β-catenin links oxidative stress to podocyte injury and proteinuria[J].Kidney Int,2019,95(4):830-845. [11] 冯敬芳.百令胶囊联合醋酸泼尼松对肾病综合征患者治疗作用探讨[J].辽宁中医药大学学报,2019,21(2):209-212.
2023, Vol. 40 
